Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)

Jorge E. Cortes, MD, Giuseppe Saglio, MD, Michele Baccarani, MD, Hagop M. Kantarjian, MD, Jiří Mayer, MD, Concepción Boqué, PhD, Neil P. Shah, MD PhD, Charles Chuah, MD, Luis Casanova, MD, Geetha Narayanan, MD DM, Brigid Bradley-Garelik, MD MPH, George Manos, PhD, Andreas Hochhaus, MD

Blood (2014) 124 (21): 152.

https://doi.org/10.1182/blood.V124.21.152.152

Published: 2014

Journal Articles

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Vikram Mathews, MD, Biju George, MD, Farah Jijina, MD, Cecil Ross, MD, Reena Nair, MD, Shashikant Apte, MD, Geetha Narayanan, MD, Atul Sharma, MD, Kavitha M Lakshmi, MSc, Auro Viswabandya, MD, Ezhilarasi Chendamarai, MSc, Poonkuzhali Balasubramanian, Ph.D, Vivi Srivastava, MD, Mammen Chandy, MD, Alok Srivastava, MD

Blood (2011) 118 (21): 426.

https://doi.org/10.1182/blood.V118.21.426.426

Published: 2011

Journal Articles

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Ruth Pettengell, FRACP, PhD, Pier Luigi Zinzani, MD, PhD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Bertrand Coiffier, MD, PhD, Gary Schiller, MD, David A. Rizzieri, MD, Paul Cernohous, MS, Lixia Wang, PhD, Jack Singer, MD

Blood (2010) 116 (21): 2833.

https://doi.org/10.1182/blood.V116.21.2833.2833

Published: 2010

Journal Articles

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

Ruth Pettengell, MD, Bertrand Coiffier, MD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Pier Luigi Zinzani, MD, Gary J Schiller, MD, David A Rizzieri, MD, Paul Cernohous, Lixia Wang, Jack W. Singer, MD

Blood (2009) 114 (22): 1677.

https://doi.org/10.1182/blood.V114.22.1677.1677

Published: 2009

Journal Articles

Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04).

Vikram Mathews, MD, Biju George, MD, Farah Jijina, MD, Cecil Ross, MD, Reena Nair, MD, Shashikant Apte, MD, Geetha Narayanan, MD, Atul Sharma, MD, Kavitha M Lakshmi, Auro Viswabandya, MD, Ezhilarasi Chendamarai, Poonkuzhali Balasubramanian, Vivi Srivastava, MD, Alok Srivastava, MD, Mammen Chandy, MD

Blood (2009) 114 (22): 2082.

https://doi.org/10.1182/blood.V114.22.2082.2082

Published: 2009

Journal Articles

A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma

Edward A. Stadtmauer, MD, David Siegel, MD, PhD, Dan T Vogl, MD, MS, James Stinnett, MD, Geetha Narayanan, MD, P.P. Bapsy, MD, Trivadi Ganesan, MBBS, MD, MNAMS, FRCP, MA, PhD, Minish Jain, MD, Sripada V.S.S Prasad, MD, DMs, Douglas S McNair, MD, PhD, Linda DeYoung, PhD, Alice Lane, Bruce Silver, MD

Blood (2008) 112 (11): 5188.

https://doi.org/10.1182/blood.V112.11.5188.5188

Published: 2008

NARROW

Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04).

A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04).

A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only